Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
English Version English Version
  MedUni Wien  trenner  Intranet  trenner  MedUni Wien - Shop  trenner  Universitätsbibliothek  trenner  Universitätsklinikum AKH Wien  trenner
 
Krebsforschung.png
 
 
 
Hauptnavigation
  • Home
  • Mission Statement
    • Chronik
    • 50 Jahre Institut für Krebsforschung
    • Imagevideo: Institut für Krebsforschung
  • Forschung
    • Forschungsschwerpunkte
    • Forschungsgruppen
    • Wissenschaftliche Services - Core Facilities
  • Lehre
    • Vorlesungen und Seminare des Institutes
    • Universitätslehrgang Toxikologie für Postgraduierte
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Programm Malignant Diseases
    • PhD Programm Clinical and Experimental Oncology
  • Kontakt
    • Kontakt
    • Lageplan
 
Forschung / Forschungsschwerpunkte / Angewandte und experimentelle Onkologie / Martin Filipits
 
Subnavigation
  • Forschungsschwerpunkte
    • Zelluläre und molekulare Tumorbiologie
    • Angewandte und experimentelle Onkologie
      • Walter Berger
      • Martin Filipits
        • Research Projects
        • Group Members
      • Petra Heffeter
      • Michael Grusch
      • Klaus Holzmann
      • Hedwig Sutterlüty
    • Sicherheit chemischer Substanzen und Krebsprävention
    • Progression und Metastasierung von Tumoren
  • Forschungsgruppen
  • Wissenschaftliche Services - Core Facilities


Inhaltsbereich

 

Martin Filipits, Assoc. Prof. Univ.-Doz. Mag. Dr.
Gruppenleiter
E-Mail: martin.filipits [at] meduniwien [dot] ac [dot] at
Phone: +43 (0)1 40160 - 57528
Fax: +43 (0)1 40160 - 957500

Research Focus

The major aim of our research is the characterization of molecular markers which help to predict therapy response in cancer patients. These markers should allow a more rational use of existing therapies, help to identify new targets in the therapy of malignant diseases or to increase the knowledge for better therapeutic concepts and ultimately improve outcome of cancer patients. To achieve this goal, we analyze tumor tissue of cancer patients for the expression of various proteins or genetic changes.



Group Members

Videos

Selected Publications

Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.
Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer CF, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster JM, Fitzal F, Gnant M. Clin Cancer Res. 2019 May 7. pii: clincanres.0376.2019. doi: 10.1158/1078-0432.CCR-19-0376


EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.
Buder A, Setinek U, Hochmair MJ, Schwab S, Kirchbacher K, Keck A, Burghuber OC, Pirker R, Filipits M.
Target Oncol. 2019 Apr;14(2):197-203. doi: 10.1007/s11523-019-00623-x.

PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma.
Zaric B, Brcic L, Buder A, Brandstetter A, Buresch JO, Traint S, Kovacevic T, Stojsic V, Perin B, Pirker R, Filipits M.
Clin Lung Cancer. 2018 Nov;19(6):e957-e963. doi: 10.1016/j.cllc.2018.08.014.

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators.
Clin Cancer Res. 2018 Jul 1;24(13):3079-3086. doi: 10.1158/1078-0432.CCR-17-3473

Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
Buder A, Hochmair MJ, Schwab S, Bundalo T, Schenk P, Errhalt P, Mikes RE, Absenger G, Patocka K, Baumgartner B, Setinek U, Burghuber OC, Prosch H, Pirker R, Filipits M.
J Thorac Oncol. 2018 Jun;13(6):821-830. doi: 10.1016/j.jtho.2018.02.014.

 

All Publications:

PubMedDataBase

 
Drucken
 
 
© MedUni Wien | Impressum | Nutzungsbedingungen | Datenschutzerklärung | Barrierefreiheit | Kontakt